Clinical trials: malaria
Malaria
A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP
The purpose of this study is to assess the safety and efficacy of adjuvanted R21 alone and in combination with a viral-vectored vaccine regimen (constituting adjuvanted R21 + ChAd63 and MVA encoding ME-TRAP) against malaria…
- Trial name
- NCT02905019
- Testing
- R21 with Matrix-M1, ChAd63 ME-TRAP, MVA ME-TRAP
- Where
- 3 sites in United Kingdom
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2
The purpose of this study is to assess the safety, immunogenicity and efficacy of the candidate malaria vaccines ChAdOx1 LS2 and MVA LS2. Healthy adult volunteers will be recruited and vaccinated in Oxford.
- Trial name
- NCT03203421
- Testing
- ChAdOx1 LS2, MVA LS2
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAF156 at 400 mg/day (Part 1) and single dosing with KAF156 at…
- Trial name
- NCT01753323
- Testing
- KAF156
- Where
- 5 sites in Thailand, Vietnam
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Plasmodium Falciparum Malaria
Artemisinin-resistant Malaria in Cambodia
Background: Artemisinin-based combination therapies (ACTs) are the first-line treatments for malaria. ACTs are highly effective, but malaria caused by the Plasmodium falciparum parasite is becoming resistant to some ACTs.
- Trial name
- NCT01736319
- Where
- Cambodia
- Volunteers
- 561 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Vivax
Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
This is a prospective, double-blind, double-dummy, multicenter, comparative study. A total of 300 subjects will be randomized to treatment on Day 1, of which a minimum of 50 female subjects must be enrolled that display moderate…
- Trial name
- NCT02216123
- Testing
- Tafenoquine, Chloroquine, Primaquine
- Where
- 10 sites in Brazil, Colombia and 4 more
- Volunteers
- 251 people
- Sponsor
- GlaxoSmithKline
Malaria
Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1
To investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers.
- Trial name
- NCT02898779
- Testing
- Primaquine, R-Primaquine, S-Primaquine, SR Primaquine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Mississippi, Oxford
Uncomplicated Falciparum Malaria, Vivax Malaria
A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
Malaria is a major public health problem in many provinces of Afghanistan the failure rate of chloroquine (CQ) and amodiaquine (AQ) treated Plasmodium falciparum(Pf) malaria has risen to more than 60% overall and as high as 90%…
- Trial name
- NCT00682578
- Testing
- Dihydroartemisinin + Piperaquine (Artekin), artesunate-sulphadoxin/pyrimethamine, chloroquine
- Where
- 4 sites in Afghanistan
- Volunteers
- 1,086 people
- Sponsor
- University of Oxford
Malaria, Falciparum
A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)
This study is an open-label randomised trial comparing standard ACT treatment with matching triple artemisinin-based combination therapies (TACTs), evaluating efficacy in safety and tolerability.
- Trial name
- TRACII (NCT02453308)
- Testing
- ACT, TACT
- Where
- 20 sites in Bangladesh, Burma and 6 more
- Volunteers
- 1,110 people
- Sponsor
- University of Oxford
Falciparum Malaria
Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia
There are worrying signs that parasitological responses to the artemisinin drugs for uncomplicated falciparum malaria are slower than elsewhere in the world.If responses to artesunate are poor it is essential to have…
- Trial name
- NCT00493363
- Testing
- Artesunate, Artesunate + Mefloquine
- Where
- Cambodia
- Volunteers
- 40 people
- Sponsor
- University of Oxford
Malaria
Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia
The primary objective of the study is to demonstrate and quantify the protective efficacy (PE) of spatial repellent products in reducing the incidence of malaria infection in human cohorts.
- Trial name
- SR-M-IDR (NCT02294188)
- Testing
- Spatial Repellent product with active ingredient (SHIELD), Active ingredient, Spatial Repellent product without active ingredient (SHIELD)
- Where
- Indonesia
- Volunteers
- 1,519 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame
Malaria, Anemia
Optimization of Seasonal Malaria Chemoprevention (SMC) Delivery
Based in part on the pivotal studies conducted in Mali, SMC was approved by WHO as a policy for malaria control in countries with seasonal malaria transmission such as Mali in March 2012.
- Trial name
- SMC (NCT02646410)
- Testing
- FPD+NDOT, FPD+DOT, DDD+NDOT
- Where
- Mali
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- University of Bamako
Malaria, Falciparum, Anemia
Liberia Insecticide Treated Durable Wall Linings Study: Protocol for a Cluster Randomised Trial (DL)
A cluster-randomized control trial will study the effect of insecticide-treated wall lining on malaria transmission in Bomi County, Liberia.
- Trial name
- NCT02448745
- Testing
- Insecticide treated wall lining
- Where
- Liberia
- Volunteers
- 6,317 people, healthy volunteers welcome
- Sponsor
- The Mentor Initiative
Malaria Diagnosis, Malaria,Falciparum
Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections
A systematic review assessing the role, appropriateness and benefits of the active case detection strategy, both proactive and reactive, in low malaria transmission settings.
- Trial name
- NCT03511443
- Testing
- hsRDT
- Where
- Burma
- Volunteers
- 1,980 people, healthy volunteers welcome
- Sponsor
- University Research Co, LLC
Malaria, Vivax
Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse
The purpose of this two part study is to test the safety and efficacy of Tafenoquine (with Cholorquine) as a radical cure for Plasmodium vivax (P.vivax) malaria relative to the control Chloroquine.Part 1 aims to select an…
- Trial name
- NCT01376167
- Testing
- Chloroquine 600mg, Chloroquine 300mg, Tafenoquine 50mg
- Where
- 14 sites in Bangladesh, Brazil and 6 more
- Volunteers
- 851 people
- Sponsor
- GlaxoSmithKline
Malaria
Plasmodium Falciparum Clearance Rates in Response to Artesunate in Eastern Cambodia
Plasmodium falciparum parasite clearance rates (PCRs) after oral artesunate treatment of patients with uncomplicated malaria were recently found to be significantly slower in Pailin (Western Cambodia) compared to Wang Pha…
- Trial name
- NCT01240603
- Where
- Cambodia
- Volunteers
- 415 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in Uganda
Background: Malaria is a disease that affects many children and adults in Uganda and Africa. If it is not treated, it can make some people severely ill.
- Trial name
- NCT02094508
- Where
- Uganda
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum
"Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, Tanzania"
This clinical trial evaluates the advantage of prolonging the therapeutic life span of Artemether-lumefantrine from 3 days to 6 days, and addition of single low dose of Primaquine 0.25mg/kg.
- Trial name
- ALU-PQ (NCT03241901)
- Testing
- Artemether-Lumefantrine Tab 20-120mg, Primaquine Phosphate 0.25 mg/kg
- Where
- 2 sites in Tanzania
- Volunteers
- 280 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Malaria
Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites
It is possible to safely protect human volunteers immunized with P. vivax irradiated sporozoites from P. vivax challenge with live sporozoites.
- Trial name
- SPZ-Irrad (NCT01082341)
- Testing
- Immunization with P. vivax irradiated sporozoites
- Where
- Colombia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria
Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax
This is a randomized, double-blind, controlled, which seeks to compare two groups of volunteers (naive and previously exposed to malaria) who were made 3 immunizations with a synthetic derivative of the CS protein of Plasmodium…
- Trial name
- NCT02083068
- Testing
- Vaccine PvCS N+C+R, Vaccine PvCS N+C, SSN Montanide ISA-51
- Where
- Colombia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria
Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1
This is a single-center, open label study. The primary aim of this project is to develop a controlled human malaria infection transmission model ("CHMI-trans") or "challenge model" to evaluate the capacity of vaccines, biologics…
- Trial name
- CHMI-trans1 (NCT02836002)
- Testing
- Sulfadoxine-pyrimethamine (low dose), Piperaquine (low dose), Sulfadoxine-pyrimethamine (high dose)
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center